tbuckley/cabot-search huggingface dataset:
<i>UGT1A1</i> genotype effects on PK, PD and toxicities of belinostat administered by 48 h continuous infusion.
Authors: Andrew K.L. Goey, Jane B. Trepel, Tristan M. Sissung, Cody J. Peer, Min-Jung Lee, Yusuke Tomita, Sheryl Ehrlich, Christine Bryla, Arlene W. Berman, Sanjeeve Balasubramaniam, Richard Piekarz, Arun Rajan, Seth M. Steinberg, Giuseppe Giaccone, William Douglas Figg, Susan Elaine Bates
Journal: Journal of Clinical Oncology (2015)

e13581 Background: UGT1A1 plays a major role in the glucuronidation of the histone deacetylase inhibitor belinostat (BEL). Polymorphisms with reduced UGT1A1 function could result in increased BEL exposure, global protein lysine acetylation (AcK) and toxicities (tox). Methods: In a Phase I (BPE) and Phase I/II trial (BPAC), BEL (400-1000 mg/m2/24 h) was administered by 48 h continuous infusion in combination with either cisplatin (P) and etoposide (E), or P, doxorubicin (A) and cyclophosphamide (C), respectively. Pts with small cell lung cancer and other cancers of neuroendocrine origin (n = 25 in BPE) or thymic epithelial tumors (n = 26 in BPAC) were genotyped for UGT1A1 variants associated with reduced function: UGT1A1*6, UGT1A1*28 and UGT1A1*60. In both trials PK BEL parameters and clinical outcomes were monitored during cycle 1. Endpoints were associations between UGT1A1 genotype and BEL PK, AcK, and tox. Results: Carriers of UGT1A1*60 variants in BPE, had progressively higher BEL t1/2 than WTs: P= 0.0077. The effect of genotype on PK was dose-dependent, since exclusion of the lowest dose level (400 mg/m2/24 h) also lead to progressive increases in AUCs (P= 0.0037) and decreases in CL (P= 0.020) in *60 variant carriers. The incidence of Gr 3-4 thrombocytopenia, neutropenia and ΔQTc prolongation was increased in pts with *28 or *60 variant alleles (P< 0.05). UGT1A1*28 genotype status trended towards an association with AcK in PBMCs at 36h post BEL start (P= 0.075). In BPAC, with 24/26 pts receiving 400 mg/m2/24h of BEL, UGT1A1 status did not significantly affect BEL AUC, Cmax and CL (P> 0.05) nor the incidence of most tox (P> 0.05), except for Gr 3-4 thrombocytopenia which occurred more frequently in *28 carriers (P= 0.0024). Conclusions: This is the first study to simultaneously evaluate UGT1A1 genotype effects on the PK, PD and tox of BEL in combination with other chemotherapeutics. UGT1A1 status was associated with systemic exposure to BEL, AcK and the incidence of tox in the BPE trial, particularly at doses > 400 mg/m2/24h. In the BPAC trial these associations were less profound. Based on these results, genotype-based dose adjustments of BEL may be desirable regardless whether BEL is used as a single-agent or in combination.
ANALYSIS OF THE TIMING OF THORACIC ENDOVASCULAR AORTIC REPAIR AND ITS INDICATIONS AND OUTCOMES IN TYPE B AORTIC DISSECTION
Authors: Yimin Chen, Thomas Gleason, Udo Sechtem, Kevin Harris, Amit Korach, Takeyoshi Ota, Sherene Shalhub, Linda Pape, G. Chad Hughes, Kevin Greason, Kim Eagle, Daniel Montgomery, Eric Isselbacher, Christoph Nienaber, Marek Ehrlich, Himanshu Patel
Journal: Journal of the American College of Cardiology (2017)
CIRCULATING INTESTINAL FATTY ACID-BINDING PROTEIN (I-FABP) LEVELS PORTENDS HIGHER RISK OF ADVERSE CLINICAL OUTCOMES IN ADVANCED DECOMPENSATED HEART FAILURE
Authors: Takeshi Kitai, Yong-Hyun Kim, Kathryn Kiefer, Rommel Morales, Justin Grodin, W.H. Wilson Tang
Journal: Journal of the American College of Cardiology (2017)
CALCIFICATION IN THE BASAL SEPTUM, BUT NOT MEMBRANOUS SEPTAL LENGTH, PREDICTS AV CONDUCTION DISTURBANCE AND PACEMAKER IMPLANTATION FOLLOWING TRANSCATHETER AORTIC VALVE REPLACEMENT WITH A BALLOON-EXPANDABLE VALVE (S3)
Authors: Brett Oestreich, Sergey Gurevich, Mackenzi Mbai, Rosemary Kelly, Stefan Bertog, Selcuk Adabag, Prabhjot Nijjar, Santiago Garcia
Journal: Journal of the American College of Cardiology (2017)
Anemia management with erythropoietic stimulating therapies (ESTs) in patients (pts) with gastrointestinal (GI) malignancies: Results from a prospective observational study
Authors: E. Chen, K. Larholt, Q. Wang, B. Bookhart, R. McKenzie, C. Tak Piech
Journal: Journal of Clinical Oncology (2007)

19614 Background: Chemotherapy-induced anemia is a common problem for pts with GI malignancies. To assess dosing patterns and outcomes in GI malignancy pts treated with ESTs (epoetin alfa (EPO) and darbepoetin alfa (DARB), a subset analysis of an ongoing registry was conducted. Methods: Data drawn between1/04 and 10/06 from 41 U.S. oncology clinics from the Dosing and Outcomes Study of Erythropoietic Stimulating Therapies (D.O.S.E.) registry were assessed. Pts were included in this analysis if they were diagnosed with a GI malignancy (colon, rectal, gastric, esophageal, or pancreatic), = 18 years, and received = 2 doses of either EPO or DARB. Outcomes assessed included mean baseline (BL) characteristics, transfusion utilization, hemoglobin (Hb) at Weeks 4, 8, and 12 after initiation of EPO or DARB, and cumulative EST doses with associated cost (based on 9/2006 wholesale acquisition cost). Results: 186 pts (82 EPO, 104 DARB) were identified. BL characteristics were similar between treatment groups: age 64 years, 45% women, and Hb 10.5g/dL. Both groups had a similar treatment duration (7 weeks) and number of Hb determinations (7.6); however, the DARB group had significantly more office visits (EPO 7, DARB 9.8, p=.0006). The proportion of pts transfused from Week 5 to end of study and number of units transfused/pt were similar between both groups. Hb values were similar at Weeks 4 (11.1 g/dL), 8 (11.1 g/dL), and 12 (11.0 g/dL). The mean administered dose per injection was 42,143 Units for EPO and 225 mcg for DARB. Mean cumulative administered dose during the treatment episode was 296,476 Units for EPO and 1,131 mcg for DARB, resulting in a dose ratio of 262:1 (Units EPO:mcg DARB). Overall EST cost was significantly lower in the EPO group compared to the DARB group (EPO $3,608, DARB $5,028, p=.0024). Conclusions: Similar hematological outcomes for EPO- and DARB-treated pts with GI malignancies were observed. Based on observed dosing patterns and cumulative EST utilization from this prospective observational study, EST costs were 28% lower in the EPO group than the DARB group. The observed dose ratio is consistent with previously reported clinical studies. No significant financial relationships to disclose.
E-TPF (cetuximab, cisplatin, docetaxel, 5-FU) induction chemotherapy in locally advanced squamous cell carcinoma of oral cavity: A phase II study.
Authors: Hsueh-Ju Lu, Mu-Hsin Chang, Ling-Wei Wang, Shyh-Kuan Tai, Ming-Huang Chen, Pen-Yuan Chu, Muh-Hwa Yang
Journal: Journal of Clinical Oncology (2015)

e17016 Background: The managements for unresectable oral cancer are difficult because of the chemo- and radioresistance. Such resistance may be due to complex environmental carcinogens such as alcohol, smoking and betel chewing in South Asia. Although docetaxol plus cisplatin and fluorouracil (TPF) has been an effective regimen as induction chemotherapy (IC) in locally advanced head and neck cancer, whether cetuximab increase the efficiency for these unresectable oral cancer is unknown. Methods: This is a prospective, phase II, open-label study.A total of 43 patients with unresectable oral cancer were enrolled between Apr 2011 and May 2014. All of them received weekly cetuximab (loading 400mg/m2 at first week and then 250mg/m2) plus triweekly TPF (docetaxel 60mg/m2 on day 1, cisplatin 75mg/m2 on day 1, and continuous 5-fluorouracil 850mg/m2 for 4 days) for total six weeks as IC. Those with partial response and complete response were selected for definitive bio-chemoradiotherapy (Bio-CCRT) with weekly cisplatin 30mg/m2 plus weekly cetuximab 250mg/m2for 7 cycles. Primary endpoint is the objective overall response (ORR) of IC. Secondary endpoints include response for Bio-CCRT, survival and adverse events. Results: Median follow-up time was 24.9 months. All patients completed 2 cycles of E-TPF. 88.4% (38/43) of patients were response to the IC with E-TPF. 84.2% (32/38) patients complete 7 cycles of Bio-CCRT. Intend-to-treat progression-free survival and overall survival were 10.4(5.1-43.7) and 12.5(5.7-43.7) months, respectively. The most grade 3/4 adverse events of IC were leucopenia (25.0%) and febrile neutropenia (13.6%). Long term complications ( > 1 year after complete Bio-CCRT ) include trismus (23.1%), soft tissue fibrosis (15.4%), xerostomia (15.4%), dysphagia (15.4%), feeding tube insertion (15.4%). Conclusions: Cetuximab plus TPF as induction chemotherapy is effective for unresectable locally advanced oral cancer. How to design follow-up definite treatments and to manage the complications are still warranted for further studies.
Does Quantitative Heterogeneity of Human Fetal Hemoglobin (Hb F) Reveal Friends or Foes of KLF1 in Globin Gene Switching ?
Authors: Alexander E. Felice, Ruth Galdies, Joseph Borg, Godfrey Grech, Wilma Cassar, Christian A Scerri, George P Patrinos, Sjaak Philipsen
Journal: Blood (2011)
Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide
Authors: S. Munir Alam, Baptiste Aussedat, Yusuf Vohra, R. Ryan Meyerhoff, Evan M. Cale, William E. Walkowicz, Nathan A. Radakovich, Kara Anasti, Lawrence Armand, Robert Parks, Laura Sutherland, Richard Scearce, M. Gordon Joyce, Marie Pancera, Aliaksandr Druz, Ivelin S. Georgiev, Tarra Von Holle, Amanda Eaton, Christopher Fox, Steven G. Reed, Mark Louder, Robert T. Bailer, Lynn Morris, Salim S. Abdool-Karim, Myron Cohen, Hua-Xin Liao, David C. Montefiori, Peter K. Park, Alberto Fernández-Tejada, Kevin Wiehe, Sampa Santra, Thomas B. Kepler, Kevin O. Saunders, Joseph Sodroski, Peter D. Kwong, John R. Mascola, Mattia Bonsignori, M. Anthony Moody, Samuel Danishefsky, Barton F. Haynes
Journal: Science Translational Medicine (2017)

A synthetic glycopeptide mimics a key neutralizing epitope on the HIV-1 envelope and can be used to isolate HIV-1 broadly neutralizing antibodies.
DECREASES IN LEFT VENTRICULAR MASS AND NOT LEFT VENTRICULAR EJECTION FRACTION ARE ASSOCIATED WITH HEART FAILURE SYMPTOMS IN CANCER PATIENTS SIX MONTHS AFTER POTENTIALLY CARDIOTOXIC CHEMOTHERAPY
Authors: Jennifer H. Jordan, Giselle Melendez, Cynthia Suerken, Ralph D'Agostino, W. Hundley
Journal: Journal of the American College of Cardiology (2017)
TCTAP A-120 Percutaneous Coronary Intervention Versus Optimal Medical Therapy in Peripheral Arterial Disease Patients Underwent Endovascular Revascularization and Combined with Significant Coronary Artery Disease
Authors: Ji Young Park, Seung-Woon Rha, Byoung Geol Choi, Se Yeon Choi, Sang-Ho Park, Jae Kyeong Byun, Min Shim, Eun Jin Park, Jah Yeon Choi, Jae Joong Lee, Sung Hun Park, Sunki Lee, Li Hu, Jin Oh Na, Cheol Ung Choi, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh
Journal: Journal of the American College of Cardiology (2016)
A phase II trial of the proteasome inhibitor bortezomib in patients with recurrent or metastatic adenocarcinoma of the bile duct or gallbladder (NCI #6135)
Authors: M. R. Costello, N. J. Meropol, C. S. Denlinger, P. F. Engstrom, J. J. Wright, T. Li, S. Mclaughlin, M. Beard, R. Cimildoro, S. J. Cohen
Journal: Journal of Clinical Oncology (2009)

e15605 Background: There is currently no standard therapy for recurrent or metastatic cancers of the bile duct or gallbladder and available chemotherapy is of uncertain benefit. As activation of NF-κB has been described in these tumors, we initiated a phase II trial of the proteasome inhibitor bortezomib in patients with recurrent or metastatic disease. Methods: Patients with measurable metastatic or unresectable adenocarcinoma of the bile duct or gallbladder who had received up to 2 prior chemotherapy regimens were eligible. Other eligibility criteria included ECOG PS 0–2, total bilirubin ≤1.5X ULN, and ALT/AST ≤2.5 X ULN. Patients with baseline neuropathy ≥grade 2 were excluded. Bortezomib was administered at a dose of 1.3 mg/m 2 as an intravenous bolus on days 1, 4, 8, and 11 of 21 day cycles with CT evaluation every 6 weeks. The primary endpoint was response rate. Null hypothesis: PR/CR≤5%. Alternative hypothesis: PR/CR ≥20%. 35 patients were required for 90% power with an early stopping rule at 20. Results: 20 patients were enrolled: 11M/9F, PS 0/1 (7/13), 6 gallbladder /14 bile duct. There was one patient with an unconfirmed partial response, 9 patients with stable disease, and 10 patients with progressive disease. Accrual was halted after 20 patients were enrolled as the early stopping rule for futility was met. Median PFS was 48 days (95% CI [32,124]) and median OS was 284 days (95% CI [155, 513]). Grade 3/4 toxicities were observed in 13 patients (65%), most commonly fatigue (4 patients), thrombocytopenia (3 patients), hyperbilirubinemia (3 patients), and hypotension (2 patients). Other SAEs at least possibly related to bortezomib included grade 3 vasculitis (1 patient) and grade 2 meningitis (1 patient). Conclusions: Bortezomib is not an active agent in the treatment of metastatic gallbladder or biliary tract cancer. No significant financial relationships to disclose.
Protein Kinase C (PKC) α Induces Expression of Aγ-Promoter-Controlled Genes in Cellular Models of Hemoglobin Switch.
Authors: A. Di Baldassarre, C. Di Rico, T. Bonfini, A. Iacone, M. Marchisio, S. Miscia, E. Alfani, A. R. Migliaccio, G. Migliaccio
Journal: Blood (2005)
LONG-TERM OUTCOME OF NONCOMPACTION CARDIOMYOPATHY PATIENTS WITH IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS COMPARED WITH PATIENTS WITH DILATED OR HYPERTROPHIC CARDIOMYOPATHY
Authors: Kadir Caliskan, Sing-Chien Yap, Arend Schinkel, Alina Constantinescu, Michelle Michels, Olivier Manintveld, Tamas Szili-Torok, Dominic Theuns
Journal: Journal of the American College of Cardiology (2017)
DNA mismatch repair protein defects and endometrial cancer in women age 40 and younger
Authors: K. K. Shih, K. Garg, D. A. Levine, N. Kauff, N. R. Abu-Rustum, R. A. Soslow, R. R. Barakat
Journal: Journal of Clinical Oncology (2009)

5579 Background: The significance of the hereditary basis of endometrial cancer is apparent in young women with endometrial cancer. The objective of this study was to describe the incidence and prognostic implications of DNA mismatch repair protein defects in a series of patients age 40 years and younger with endometrial cancer. Methods: We performed a retrospective cohort study of patients age 40 years or less who were diagnosed with endometrial carcinoma between 1/93 and 5/08. Clinical and pathologic data were extracted from medical records. Paraffin-embedded slides from hysterectomy specimens were obtained and DNA mismatch repair (MMR) immunohistochemistry (IHC) was performed. Cases were analyzed according to presence of DNA MMR protein defects. Standard two-sided statistical tests were performed. Results: Of the 71 identified patients, the median age was 37 years (range, 24–40), with a median follow-up of 47 months (range, 1–178). The majority were of endometrioid histology (94%), stage I (73%), and FIGO grade 1 (61%). IHC was performed with available blocks (n = 56), and loss of DNA MMR was found in 9 cases (16%). Cases with loss of DNA MMR were more likely to have high-grade (FIGO 2 or 3) tumors (p &lt; 0.001), be advanced stage (III or IV) at the time of diagnosis (p &lt; 0.001), and have a family history suggestive of hereditary non-polyposis colorectal cancer (p = 0.01). There was no difference between the groups in histology, obesity (BMI&gt;30), parity, or history of infertility. Analysis of clinical outcomes revealed that cases with loss of DNA MMR had significantly worse overall survival (median survival not reached, log rank p = 0.018). At the time of last follow-up, 2 (22%) patients with loss of DNA MMR were dead of disease compared with 2 (4%) patients with retained DNA MMR. Conclusions: Endometrial cancer is rare in young women age 40 years or less. In these patients, loss of DNA MMR was associated with worse clinicopathologic factors (high-grade and advanced-stage tumors) and worse outcome. Other clinical risk factors associated with endometrial cancer were not associated with loss of DNA MMR. The data suggest that MMR testing in women 40 years of age or younger with endometrial cancer may have clinically useful prognostic information. No significant financial relationships to disclose.
Long Term Survival and Clinical Complete Responses of Various Prognostic Subgroups in 103 Relapsed/Refractory Acute Myeloid Leukemia (r/r AML) Patients Treated with Guadecitabine (SGI-110) in Phase 2 Studies
Authors: Naval Daver, Hagop M. Kantarjian, Gail J. Roboz, Patricia L. Kropf, Karen W.L. Yee, Casey L. O'Connell, Elizabeth A. Griffiths, Elias J. Jabbour, Wendy Stock, Katherine J. Walsh, David A. Rizzieri, Jesus G. Berdeja, Xiang Yao Su, Mohammad Azab, Jean-Pierre Issa
Journal: Blood (2016)
Adoptive Transfer of Autologous CD25-Depleted, CD3/CD28-Costimulated T Cells After Cyclophosphamide - Fludarabine Chemotherapy in Patients with Low-Grade Follicular Lymphoma: Long-Term Follow up
Authors: Stephen J. Schuster, Nicole A. Aqui, Benjamin Musher, Bruce L. Levine, Charalambos Andreadis, Elise A. Chong, Sunita D. Nasta, Amanda Gordon, Julio Cotte, Zhaohui Zheng, Andrea L. Brennan, Elizabeth Veloso, Carl H. June
Journal: Blood (2012)
ASP8273, a mutant-selective irreversible EGFR inhibitor in patients (pts) with NSCLC harboring EGFR activating mutations: Preliminary results of first-in-human phase I study in Japan.
Authors: Yasushi Goto, Hiroshi Nokihara, Haruyasu Murakami, Toshio Shimizu, Takashi Seto, Andrew P. Krivoshik, Anne Therese Keating, Koichi Uegaki, Kentaro Takeda, Kanji Komatsu, Satoshi Morita, Masahiro Fukuoka, Kazuhiko Nakagawa
Journal: Journal of Clinical Oncology (2015)

8014 Background: ASP8273 is a small molecule, irreversible tyrosine kinase inhibitor (TKI) that inhibits the kinase activity of EGFR activating mutations and T790M resistance mutation, with higher potency than wild type EGFR. Methods: NSCLC pts previously treated with at least an EGFR-TKI were enrolled into this open-label Phase I/II study which consists of a dose escalation and response expansion cohorts followed by the P2 at the RP2D. ASP8273 was administered orally once daily. All pts were assessed for AEs, PK and anti-tumor activity. In each dose-escalation cohort at least 3 pts were enrolled regardless of T790M status and in response expansion cohorts only pts with T790M were enrolled (NCT02192697). Results: As of 14 Nov. 2014, 30 Japanese pts were enrolled across 7 dose levels (25 - 600 mg) in the dose-escalation cohorts and 15 pts were enrolled in the response expansion cohorts at 4 dose levels (100 - 400 mg). Demographics of the pts were median age 65 yrs, 73% female, 62% ECOG PS1 and 51% received immediate prior EGFR-TKI. T790M status was 49% positive, 13% negative and 38% unknown, respectively. Most common AEs were diarrhea (56%), nausea (31%), vomiting (31%) and platelet count decreased (31%). A few events of rash (9%), QTc prolongation (7%), ILD-like events (2%) and no hyperglycemia have been reported. 9 DLTs were reported at doses of 400 – 600 mg (3 diarrhea, 2 colitis, 1 biliary tract infection, 2 nausea and 1 hyponatremia). Based on these safety findings, MTD was determined to be 400 mg. Median AUC and Cmax after single- and multiple-dose of ASP8273 were increased with dose, respectively. RECIST responses were observed in pts enrolled in ≥ 100 mg. 50% (18/36) of all evaluable pts and 80% (12/15) pts with T790M have achieved PRs (includes confirmed and unconfirmed PRs). 300 mg once daily was chosen as RP2D based on the available safety, PK and anti-tumor activity data. Conclusions: ASP8273 under MTD has demonstrated anti-tumor activity in NSCLC pts with tumors harboring both EGFR activating mutations and T790M resistance mutation. The phase 2 part of this study will further investigate the clinical activity of ASP8273 at the RP2D in pts with T790M. Clinical trial information: NCT02192697.
COMPARATIVE STUDY ON CATHETER-DIRECTED THROMBOLYSIS – CONTINUOUS TISSUE PLASMINOGEN ACTIVATOR VERSUS ANGIOJET CATHETER POWER PULSE SPRAY RHEOLYTIC THROMBECTOMY OUTCOME STUDY: SINGLE-CENTER EXPERIENCE
Authors: Khalil Odeh, Rafath Ullah, Hani Hashim, Susan Olet, Tanvir Bajwa, Suhail Allaqaband, M. Fuad Jan
Journal: Journal of the American College of Cardiology (2017)
Case series of hypomethylating agents (HMA) effect on myelodysplastic/myeloproliferative neoplasm unclassified (MDS/MPN-U): Mayo Clinic experience.
Authors: Ahmed K. Abou Hussein, Mrinal Mahesh Patnaik, Darci Zblewski, Naseema Gangat, Shahrukh Hashmi, Michelle A. Elliott, William J. Hogan, Mark Robert Litzow, Aref Al-Kali
Journal: Journal of Clinical Oncology (2015)

7088 Background: MDS/MPN-U is a rare myeloid disorder that has both dysplastic and proliferative features, but cannot be parsimoniously classified as either MDS or MPN. There is currently no standard treatment algorithm for MDS/MPN-U and is either based on MPN or MDS best available therapies. Methods: A retrospective, single-institution study between 1993-2014 of WHO-defined MDS/MPN-U cases was carried after getting appropriate IRB approval. Patients with diagnosis of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts were excluded. Wilcoxon, Pearson tests, Kaplan Meier, multivariant analysis were done via JMP 10. Results: A total of 63 patients with MDS/MPN-U were identified, 10 of whom were treated with HMA. The indication for treatment was thrombocytopenia in 50%, anemia in 30%, and symptomatic splenomegaly in 20%. Median age was 67.5 years (56-82), with 80% of the patients were males. Median platelet count was 101 x109 (14-184), hemoglobin (Hg) of 9.4 g/dL (6.9-16.3), white blood cell (WBC) count of 8.3 x109(1.8-90.7), peripheral blood blasts of 1% (0-6); bone marrow blasts of 5% (3-20). Cytogenetics were diploid in 70%, while splenomegaly was found in 30%. Two HMAs were used, with decitabine in 60% and azacitidine in the other 40%. There was no statistical significance on overall survival (OS) between the two HMAs (p = 0.2). The median number of treatment cycles was 5 (1-20), with achievement of complete response (CR) in 20%, partial response (PR) in 10%, stable disease in 40%, and progressive disease in 30%. Transformation to AML was seen in 40%, with a median time of 372 days (248-929). Bone marrow transplant was performed in one patient. Median OS was 15 months. Multivariate analysis revealed bone marrow blasts (p = 0.01) as the only statistically significant factor on OS (but not WBC, Hg or platelets). Conclusions: MDS/MPN-U is a rare entity with no standard treatment algorithm available at present. HMAs yielded an overall response (CR+PR) of 30%, with a median OS of 15 months. On a multivariate analysis only bone marrow blasts had an impact on mOS. Larger studies are needed to confirm our findings in this rare disease.
ATHEROSCLEROTIC PLAQUE MORPHOLOGY IS ASSOCIATED WITH IMPAIRED MYOCARDIAL BLOOD FLOW AND FRACTIONAL FLOW RESERVE, INDEPENDENT OF LUMINAL OBSTRUCTION
Authors: Roel Driessen, Wijnand Stuijfzand, Pieter Raijmakers, Ibrahim Danad, James Min, Jonathon Leipsic, Amir Ahmadi, Jagat Narula, Peter van de Ven, Marc Huisman, Adriaan Lammertsma, Albert van Rossum, Niels Van Royen, Paul Knaapen
Journal: Journal of the American College of Cardiology (2017)